Advanced melanoma survival improves significantly when immunotherapy is given before targeted therapy

A clinical trial showed a remarkable 20 percent advantage in the two-year overall survival rate for people with advanced melanoma who first received immunotherapy (72 percent survival rate) versus those who initially got targeted therapies (52 percent survival rate). Progression-free survival, where the cancer is stable or improving, was also trending in favor of those who started on immunotherapy.

from Latest Science News -- ScienceDaily https://ift.tt/NFrCxJj